This is an open-label multicenter randomized non comparative phase II study to evaluate the
safety and efficacy of the monoclonal anti-KIR3DL2 antibody Lacutamab in patients with
Refractory/Relapsing (R/R) KIR3DL2 positive Peripheral T Cell Lymphoma (PTCL) : Not Other
Specified (NOS), PTCL-TFH (including Angioimmunoblastic T-cell Lymphoma (AITL), Follicular
T-cell lymphoma, Nodal peripheral T-cell lymphoma with TFH phenotype), Anaplastic large cell
lymphoma (ALCL), Adult T-cell leukemia/lymphoma (ATL), Hepatosplenic T-cell lymphoma (HSTL),
Enteropathy-associated T-cell lymphoma (EATL), Monomorphic epitheliotropic intestinal T cell
lymphoma (MEITL), NK-T cell lymphoma (NKT) and Aggressive NK-cell leukemia (ANKL).
The design is non comparative meaning that non comparison between arms will be performed as
the control arm will ensure that the assumptions used for sample size calculation are
verified. For that reason, randomization is unbalanced in favor of the experimental arm
(2:1).